Pulse May 2019 issue - Page 9

Treatment Guidelines Support Early and Regular Assessment of Treatment Response in Major Depressive Disorder (MDD)† 1-3 – Why? About one third of patients with MDD do not respond to an initial trial of antidepressant therapy. 4,5 Early identification of patients that will not benefit from a particular type of treatment can minimise unnecessary drug exposure and resource use. 6 NICE*, The Maudsley Prescribing Guidelines and the British Association for Psychopharmacology recommend to assess response to antidepressant medication between 2-6 weeks and act swiftly if no effect is seen within this period. † 1-3 *©NICE 2019 Depression in adults: recognition and management. Available from www.nice.org.uk/guidance/cg90 All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this publication. †Refer to the Summary of Product Characteristics (available at www.medicines.org.uk) for each specific medication, to find out more about the relevant time-period to assess patient treatment response. References: 1. Taylor D et al. The Maudsley Prescribing Guidelines in Psychiatry. 13th Ed. 2018. Chichester: Wiley. 2. NICE. Depression in adults: treatment and management. Consultation draft May 2018 (online). [Accessed April 2019]. 3. Cleare A et al. J Psychopharmacol. 2015; 29(5): 459-525. 4. Al-Harbi KS. Patient Prefer Adherence. 2012; 6: 369-388. 5. Keller MB. J Clin Psychiatry. 2005; 66(Suppl 8): 5-12. 6. Szegedi A et al. J Clin Psychiatry. 2009; 70(3): 344-353. Item code: CP-73232 Date of preparation: April 2019